Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,193,609
  • Shares Outstanding, K 157,787
  • Annual Sales, $ 1,171 M
  • Annual Income, $ -196,620 K
  • 60-Month Beta 1.97
  • Price/Sales 2.75
  • Price/Cash Flow 35.13
  • Price/Book 2.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.37
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.65 +21.56%
on 02/14/20
20.74 -2.41%
on 02/21/20
+1.72 (+9.26%)
since 01/21/20
3-Month
16.65 +21.56%
on 02/14/20
21.88 -7.50%
on 11/25/19
+0.16 (+0.80%)
since 11/21/19
52-Week
16.65 +21.56%
on 02/14/20
37.75 -46.38%
on 04/09/19
-12.33 (-37.86%)
since 02/21/19

Most Recent Stories

More News
Alkermes Plc has the Best Relative Performance in the Biotechnology Industry (ALKS , AKBA , CLVS , ARDX , BLUE )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AKBA : 10.15 (-0.88%)
ALKS : 20.24 (-0.93%)
CLVS : 11.00 (+2.09%)
SmarTrend Watching for Potential Pullback in Shares of Alkermes Plc After 5.30% Gain

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $18.70 to a high of $19.75. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high of $18.82...

ALKS : 20.24 (-0.93%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CLVS , ALKS , PBYI , AKBA , AMAG )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALKS : 20.24 (-0.93%)
CLVS : 11.00 (+2.09%)
PBYI : 13.60 (-2.58%)
Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26, 2020 at 9:00 a.m. ET (2:00 p.m. GMT)...

ALKS : 20.24 (-0.93%)
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4

Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.

BIIB : 336.71 (+0.02%)
JNJ : 149.93 (+1.05%)
ALKS : 20.24 (-0.93%)
GH : 88.81 (+1.59%)
Watch for Alkermes Plc to Potentially Rebound After Falling 5.81% Yesterday

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $17.93 to a high of $19.97. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $18.80...

ALKS : 20.24 (-0.93%)
Alkermes (ALKS) Tops Q4 Earnings and Revenues Beat Estimates

Alkermes beats earnings and sales estimates in the fourth quarter of 2019.

ALKS : 20.24 (-0.93%)
Alkermes: 4Q Earnings Snapshot

DUBLIN (AP) _ Alkermes PLC (ALKS) on Thursday reported a loss of $5.4 million in its fourth quarter.

ALKS : 20.24 (-0.93%)
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for 2020.

ALKS : 20.24 (-0.93%)
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?

We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.

BIIB : 336.71 (+0.02%)
ALKS : 20.24 (-0.93%)
NKTR : 23.53 (-0.59%)
ASND : 141.90 (-2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 21.03
1st Resistance Point 20.63
Last Price 20.24
1st Support Level 19.95
2nd Support Level 19.67

See More

52-Week High 37.75
Fibonacci 61.8% 29.69
Fibonacci 50% 27.20
Fibonacci 38.2% 24.71
Last Price 20.24
52-Week Low 16.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar